Accepted for/Published in: JMIR Research Protocols
Date Submitted: Jul 17, 2024
Open Peer Review Period: Jul 21, 2024 - Sep 15, 2024
Date Accepted: Apr 4, 2025
(closed for review but you can still tweet)
Assessing the Role of Blood Group Genotyping in Predicting Hemolysis in Thalassemia Beta Major Patients with Repeated Transfusions: A Protocol for a Cross-Sectional Study
ABSTRACT
Background:
Hemolytic transfusion reactions are a major complication in patients with thalassemia beta major receiving regular transfusions. These reactions can be influenced by blood group incompatibilities, particularly in settings with limited genotyping practices. In Indonesia, the role of blood group genotyping in predicting hemolysis has not been thoroughly studied. This study aims to analyze the association between blood group genotyping and the incidence of hemolysis in thalassemia patients undergoing repeated transfusions.
Methods:
This is a cross-sectional study involving patients with thalassemia beta major under 18 years old who received regular transfusion with intervals of 2-4 weeks and have received more than 20 units of transfusion. Subjects with leukemia, lymphoproliferative diseases, diabetes, solid tumors, and immunosuppression disorders were excluded from the study. Genotyping examination was conducted using PCR ASP while phenotyping was examined using immunoserology. Follow-up gene sequencing was conducted to observe the blood group variants. Hemolysis was assessed using several markers such as haptoglobulin, free hemoglobin, LDH, bilirubin, hemoglobinurin, measured by Cobas C113, ELISA and urinalysis.
Results:
Clinical and laboratory data is completed. A total of 90 samples were collected, data analyses are undertaken, and the first results reporting findings is expected to be in September 2024. Conclusions The results of this study will provide information on blood groups system that can predict hemolysis occurrence in thalassemia beta major patients with repeated transfusion. This data will contribute to the best possible patient care management and blood transfusion therapy, thereby reducing the risk of hemolysis and improving the quality of life for thalassemia patients in Indonesia.
Citation
Request queued. Please wait while the file is being generated. It may take some time.
Copyright
© The authors. All rights reserved. This is a privileged document currently under peer-review/community review (or an accepted/rejected manuscript). Authors have provided JMIR Publications with an exclusive license to publish this preprint on it's website for review and ahead-of-print citation purposes only. While the final peer-reviewed paper may be licensed under a cc-by license on publication, at this stage authors and publisher expressively prohibit redistribution of this draft paper other than for review purposes.